Previous 10 | Next 10 |
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2020 and provide a corpo...
OTIC failed a phase 3 trial and fell from $20 to $5, and hasn't recovered since despite succeeding in another phase 3. A tiebreaker third phase 3 is ongoing with data by 1Q2021. If successful, the stock may have a surge. For further details see: Otonomy And Its Efforts A...
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in a fireside chat at the virtual H.C. Wainwright ...
Otonomy (OTIC) gains 10% in premarket on the heels of positive top-line results from Phase 1/2 trial evaluating OTO-413 in subjects with speech-in-noise hearing difficulty. Results include the 9 subjects from the OTO-413 high dose (0.3 mg) cohort with test results on both Day 5...
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests A single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to continue clinical development of OTO-413 Management will review...
After review of Otonomy's ([[OTIC]] +0.7%) Otividex statistical analysis plan, the FDA confirms use of the Negative Binomial model for analysis of the primary endpoint in the ongoing Phase 3 trial in Ménière’s disease (inner ear disorder). As previously reported, en...
FDA’s review confirms use of Negative Binomial m odel for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease ; results still expected in fir...
Otonomy, Inc. (OTIC) Q3 2020 Earnings Conference Call November 4, 2020 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC David Weber - President, CEO & Director Paul Cayer - Chief Financial & Business Officer Conference Call Participants Tara Bancroft - Piper Sandl...
Otonomy, Inc. (OTIC) Q3 2020 Earnings Conference Call October 4, 2020 4:20 PM ET Company Participants Robert Uhl - Westwicke Partners David Weber - President, CEO & Director Conference Call Participants Tara Bancroft - Piper Sandler & Co. Oren Livnat - H.C. Wainwright & Co Francoi...
Otonomy (OTIC): Q3 GAAP EPS of -$0.22 beats by $0.02.Revenue of $0.05M (-61.5% Y/Y) misses by $0.01M.FY2020 guidance: Non-GAAP operating expenses of $35M-$38M , GAAP operating expenses of $45M-$48M. Cash equivalents, and short-term investments will be sufficient to fund the company’s o...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...